Preventing Posttraumatic Stress Disorder by Facing Trauma Memories
Reports new study in Biological Psychiatry
Philadelphia, PA, November 27, 2012 – Posttraumatic stress disorder (PTSD) is a form of learning that begins at the moment of the exposure to extremely stressful situations and that grows in impact as trauma-related memories are rehearsed and strengthened repeatedly. This somewhat oversimplified view of PTSD yields a powerful prediction: if one could disrupt the rehearsal and strengthening of traumatic memories, a process called reconsolidation of memories, then one might reduce PTSD risk or PTSD severity after potentially traumatic events.
To be certain, it is tricky to attempt to alter traumatic memory reconsolidation. In fact, some early strategies for “trauma debriefing” turned out to strengthen rather than diminish posttraumatic learning.
Despite these challenges, a new study by Dr. Barbara Rothbaum and colleagues reports that a behavioral intervention delivered to patients immediately post-trauma is effective at reducing posttraumatic stress reactions.
“PTSD is a major public health concern,” said Rothbaum, professor in Emory's Department of Psychiatry and Behavioral Sciences. “In so many people, what happens immediately after a traumatic event can make things worse or better. Right now, there are no accepted interventions delivered in the immediate aftermath of trauma.”
To conduct the study, the researchers approached patients who presented to the local emergency room due to a traumatic event, including rape, car accident, or physical assault. Half of those who agreed to participate received the behavioral intervention, which was started immediately, while the other half did not. All patients were repeatedly assessed for symptoms of depression and stress over a twelve-week period.
The intervention is a modified form of exposure therapy in which a survivor confronts anxiety about a traumatic event by recounting it. Administered over the course of 3 1-hour sessions, the goal is to alter the person’s thoughts and feelings about the traumatic event. Trained therapists asked the participants to describe the trauma they just experienced and recorded the description. The patients were instructed to listen to their recordings every day. The therapists also helped the patients look at obtrusive thoughts of guilt or responsibility, and taught them a brief breathing relaxation technique and self care.
They found that the intervention was safe, feasible, and successful at reducing posttraumatic stress reactions, compared to those who were assigned to the assessment-only condition, at 4 and 12 weeks post-injury.
“This study provides an elegant and clinically important test of the trauma reconsolidation hypothesis,” commented Dr. John Krystal, editor of Biological Psychiatry.
The implications of this study are immense, Rothbaum explained. “If we know what to do, then we can train emergency workers to intervene with patients on a large scale. In addition to being implemented in the emergency room, it can help on the battlefield, in natural disasters, or after criminal assaults.”
She concluded, “More research is needed, but this prevention model could have significant public health implications. A long-standing hope of mental health research is to prevent the development of psychopathology in those at risk instead of being limited to symptom treatment after disease onset.”
The article is “Early Intervention May Prevent the Development of Posttraumatic Stress Disorder: A Randomized Pilot Civilian Study with Modified Prolonged Exposure” by Barbara Olasov Rothbaum, Megan C. Kearns, Matthew Price, Emily Malcoun, Michael Davis, Kerry J. Ressler, Delia Lang, and Debra Houry (doi: 10.1016/j.biopsych.2012.06.002). The article appears in Biological Psychiatry, Volume 72, Issue 11 (December 1, 2012), published by Elsevier.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Rhiannon Bugno at +1 214 648 0880 or Biol.Psych@utsouthwestern.edu. Journalists wishing to interview the authors may contact Kathi Baker at +404 727 9371 or email@example.com.
The authors’ affiliations, and disclosures of financial and conflicts of interests are available in the article.
John H. Krystal, M.D., is Chairman of the Department of Psychiatry at the Yale University School of Medicine and a research psychiatrist at the VA Connecticut Healthcare System. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry
Biological Psychiatry is the official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal publishes both basic and clinical contributions from all disciplines and research areas relevant to the pathophysiology and treatment of major psychiatric disorders.
The journal publishes novel results of original research which represent an important new lead or significant impact on the field, particularly those addressing genetic and environmental risk factors, neural circuitry and neurochemistry, and important new therapeutic approaches. Reviews and commentaries that focus on topics of current research and interest are also encouraged.
Biological Psychiatry is one of the most selective and highly cited journals in the field of psychiatric neuroscience. It is ranked 5th out of 129 Psychiatry titles and 16th out of 243 Neurosciences titles in the Journal Citations Reports® published by Thomson Reuters. The 2011 Impact Factor score for Biological Psychiatry is 8.283.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
+1 214 648 0880